Royalty Pharma plcRPRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 8.54% | 38.0M | — | 2024-02-13 |
| FMR LLC | 7.10% | 31.6M | — | 2024-02-09 |
| General Atlantic, L.P. | 5.60% | 26.3M | — | 2024-02-13 |
| M. Germano Giuliani | 2.30% | 10.3M | — | 2024-07-29 |
Insider Transactions
Net 90d: −$17.65M · buys $0 / sells $17.65MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 1.9K | $48.33 | $90.6K |
| 2026-04-01 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 32.9K | $48.33 | $1.59M |
| 2026-03-31 | Bassler Bonnie L | Director | Grant | 815 | $45.98 | $37.5K |
| 2026-03-23 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 32.9K | $45.53 | $1.50M |
| 2026-03-23 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 1.9K | $45.53 | $85.4K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 22.5K | $46.67 | $1.05M |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 10.4K | $47.01 | $490.3K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 1.3K | $46.67 | $60.3K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 583 | $47.01 | $27.4K |
| 2026-02-23 | Coyne Terrance P. | EVP & CFO | Sell (open market) | 32.9K | $45.32 | $1.49M |
1–10 of 22
Page 1 / 3